Search

Your search keyword '"Muguruma, Kazuya"' showing total 293 results
Start Over Author "Muguruma, Kazuya" Language english
293 results on '"Muguruma, Kazuya"'

19. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)

Author

Tanaka, Hiroaki, Kanda, Mitsuro, Morita, Satoshi, Taguri, Masataka, Nishikawa, Kazuhiro, Shimada, Mitsuo, Muguruma, Kazuya, Koeda, Keisuke, Takahashi, Masazumi, Nakamori, Mikihito, Konno, Hiroyuki, Tsuji, Akihito, Hosoya, Yoshinori, Shirasaka, Tetsuhiko, Yamamitsu, Susumu, Sowa, Michio, Kitajima, Masaki, Okajima, Masazumi, Kobayashi, Michiya, Sakamoto, Junichi, Saji, Shigetoyo, and Hirakawa, Kosei

Published
2017
Full Text
View/download PDF

42. Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma

Author

Tatsuwaki, Hiroshi, Tanigawa, Tetsuya, Watanabe, Toshio, Machida, Hirohisa, Okazaki, Hirotoshi, Yamagami, Hirokazu, Shiba, Masatsugu, Watanabe, Kenji, Tominaga, Kazunari, Fujiwara, Yasuhiro, Oshitani, Nobuhide, Muguruma, Kazuya, Sawada, Tetsuji, Hirakawa, Kosei, Higuchi, Kazuhide, and Arakawa, Tetsuo

Published
2010
Full Text
View/download PDF

44. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer.

Author

Mori, Takuya, Tanaka, Hiroaki, Deguchi, Sota, Yamakoshi, Yoshihito, Miki, Yuichiro, Yoshii, Mami, Tamura, Tatsuro, Toyokawa, Takahiro, Lee, Shigeru, Muguruma, Kazuya, and Ohira, Masaichi

Subjects
TERTIARY structure, NIVOLUMAB, DRUG side effects, STOMACH cancer, T cells, IMMUNOLOGIC memory
Abstract

Nivolumab, an immune checkpoint blocker, has been approved for advanced gastric cancer (GC), but predictive factors of nivolumab's efficacy in patients with GC, especially immune cells such as tissue-resident memory T cells or those forming tertiary lymphoid structures (TLS), remain unclear. Tissue samples were obtained from surgically resected specimens of patients with GC who were treated with nivolumab as third-line or later treatment. Immunohistochemical staining was performed to detect the presence of TLS and CD103+ T cells and assess the association between TLSs and response to nivolumab treatment. A total of 19 patients were analyzed. In patients with partial response (PR) to nivolumab, numerous TLS were observed, and CD103+ T cells were found in and around TLS. Patients with many TLS experienced immune-related adverse events more often than those with few TLS (p = 0.018). The prognosis of patients with TLS high was better than those with TLS low. Patients with a combination of TLS high and CD103 high tended to have a better prognosis than other groups. Our results suggested that TLS status might be a predictor of nivolumab effectiveness. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. The clinicopathologic significance of Tks5 expression of peritoneal mesothelial cells in gastric cancer patients.

Author

Sugimoto, Atsushi, Okuno, Tomohisa, Tsujio, Gen, Sera, Tomohiro, Yamamoto, Yurie, Maruo, Koji, Kushiyama, Shuhei, Nishimura, Sadaaki, Kuroda, Kenji, Togano, Shingo, Miki, Yuichiro, Yoshii, Mami, Tamura, Tatsuro, Toyokawa, Takahiro, Tanaka, Hiroaki, Muguruma, Kazuya, Ohira, Masaichi, and Yashiro, Masakazu

Subjects
STOMACH cancer, CANCER patients, LYMPHATIC metastasis, ADAPTOR proteins, CANCER cells
Abstract

Background: Gastric cancer (GC) patients frequently develop peritoneal metastasis. Recently, it has been reported that peritoneal mesothelial cells (PMCs) activated by GC cells acquire a migratory capacity and promote GC cell invasion. The invasiveness of PMCs reportedly depends on the activity of Tks5, an adaptor protein required for invadopodia formation. However, the relationship between clinicopathologic features and Tks5 expression in PMCs has been poorly documented. In this study, we evaluated the clinicopathologic significance of the Tks5 expression of PMCs in GC patients. Materials and methods: A total of 110 GC patients who underwent gastrectomy were enrolled in this study. Tks5 expressions in PMCs from the greater omentum, lesser omentum and retroperitoneum were evaluated by immunohistochemistry. We analyzed the correlation between Tks5 expressions in PMCs and the patients' clinicopathologic features. Results: Tks5 expression was found in 71 (64.5%) of the 110 patients, while 39 (35.5%) were Tks5-negative. Tks5 positivity was significantly (p = 0.038) associated with a greater tumor depth (i.e., T3/4 compared with T1/T2). Peritoneal recurrence was found in 12 of 98 cases within 3 years of surgery. The 3-year peritoneal recurrence-free survival (PRFS) rate in Tks5-positive cases was significantly poorer than that in Tks5-negative cases (80.1% vs 97.4%, p = 0.024). Multivariate analysis revealed that Tks5 positivity and lymph node metastasis were independent factors for PRFS. Conclusion: Tks5 is frequently expressed in PMCs in advanced-stage gastric cancer. Tks5 might be a useful predictor for peritoneal recurrence in GC patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Tertiary lymphoid structures show infiltration of effective tumor‐resident T cells in gastric cancer.

Author

Mori, Takuya, Tanaka, Hiroaki, Suzuki, Shugo, Deguchi, Sota, Yamakoshi, Yoshihito, Yoshii, Mami, Miki, Yuichiro, Tamura, Tatsuro, Toyokawa, Takahiro, Lee, Shigeru, Muguruma, Kazuya, Wanibuchi, Hideki, and Ohira, Masaichi

Abstract

Several studies have reported that tissue‐resident memory T cells (TRM cells) or tertiary lymphoid structures (TLSs) are associated with a good prognosis. The aim of this study was to clarify the association of TRM cells and TLSs in the tumor immune microenvironment in gastric cancer (GC). We performed immunohistochemical and immunofluorescence staining to detect the presence of CD103+ T cells and to assess the association between CD103+ T cells and TLSs. CD103+ T cells were observed in the tumor epithelium accompanied by CD8+ T cells and were associated with a better prognosis in GC. Furthermore, CD103+ T cells were located around TLSs, and patients with CD103high had more rich TLSs. Patients who had both CD103high cells and who were TLS‐rich had a better prognosis than patients with CD103low cells and who were TLS‐poor. Moreover, for patients who received PD‐1 blockade therapy, CD103high and TLS‐rich predicted a good response. Flow cytometry was performed to confirm the characteristics of CD103+CD8+ T cells and showed that CD103+CD8+ T cells in GC expressed higher levels of PD‐1, granzyme B, and interferon‐γ than CD103−CD8+ T cells. Our results suggested that CD103+CD8+ cells in GC are correlated with TLSs, resulting in enhanced antitumor immunity in GC. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Phosphorylated Smad2 in Advanced Stage Gastric Carcinoma

Author

Doi Yosuke, Tanaka Hiroaki, Kubo Naoshi, Noda Satoru, Matsuzaki Taro, Kaizaki Ryoji, Nishii Takafumi, Toyokawa Takahiro, Yashiro Masakazu, Shinto Osamu, Ohira Masaichi, Muguruma Kazuya, Sawada Tetsuji, and Hirakawa Kosei

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Transforming growth factor β (TGFβ) receptor signaling is closely associated with the invasion ability of gastric cancer cells. Although Smad signal is a critical integrator of TGFβ receptor signaling transduction systems, not much is known about the role of Smad2 expression in gastric carcinoma. The aim of the current study is to clarify the role of phosphorylated Smad2 (p-Smad2) in gastric adenocarcinomas at advanced stages. Methods Immunohistochemical staining with anti-p-Smad2 was performed on paraffin-embedded specimens from 135 patients with advanced gastric adenocarcinomas. We also evaluated the relationship between the expression levels of p-Smad2 and clinicopathologic characteristics of patients with gastric adenocarcinomas. Results The p-Smad2 expression level was high in 63 (47%) of 135 gastric carcinomas. The p-Smad2 expression level was significantly higher in diffuse type carcinoma (p = 0.007), tumours with peritoneal metastasis (p = 0.017), and tumours with lymph node metastasis (p = 0.047). The prognosis for p-Smad2-high patients was significantly (p = 0.035, log-rank) poorer than that of p-Smad2-low patients, while a multivariate analysis revealed that p-Smad2 expression was not an independence prognostic factor. Conclusion The expression of p-Smad2 is associated with malignant phenotype and poor prognosis in patients with advanced gastric carcinoma.

Published
2010
Full Text
View/download PDF

50. Clinical benefit for clinical sequencing using cancer panel testing.

Author

Nishimura, Sadaaki, Sugimoto, Atsushi, Kushiyama, Shuhei, Togano, Shingo, Kuroda, Kenji, Yamamoto, Yurie, Yamauchi, Makoto, Sumi, Toshiyuki, Kaneda, Hiroyasu, Kawaguchi, Tomoya, Kato, Minoru, Tagami, Mizuki, Oebisu, Naoto, Hoshi, Manabu, Kimura, Kenjiro, Kubo, Shoji, Muguruma, Kazuya, Takashima, Tsutomu, Ohira, Masaichi, and Yashiro, Masakazu

Subjects
PHARMACOGENOMICS, GENES, GENE amplification, GENE frequency, OFF-label use (Drugs), GENETIC testing
Abstract

Background: Clinical sequencing using a panel of genes has recently been applied worldwide for patients with refractory solid tumors, but the significance of clinical sequencing using gene panel testing remains uncertain. Here we sought to clarify the feasibility and utility of clinical sequencing in the treatment of refractory tumors at our hospital. Methods: A total of 39 patients with advanced solid tumors treated at our hospital between 2018 and 2020 were enrolled in the clinical sequencing. Among them, we identified 36 patients whose tissue samples were of suitable quality for clinical sequencing, and we analyzed the genomic profiles of these tumors. Results: Pathogenic alterations were detected in 28 (78%) of the 36 patients. The most common mutation was TP53 (55%), followed by KRAS (22%), and the highest frequency of gene amplification was ERBB2 (17%). Nine of the 36 patients were identified as candidates for novel molecular-targeted therapy based on their actionable gene alterations, but only one case ended up receiving novel targeted therapy following the genetic tests. Conclusions: Our current results suggested that clinical sequencing might be useful for the detection of pathogenic alterations and the management of additional cancer treatment. However, molecular target based on actionable genomic alteration does not always bridge to subsequent therapy due to clinical deterioration, refusal for unapproved drug, and complexity of clinical trial access. Both improved optimal timing of clinical sequencing and a consensus about its off-label use might help patients receive greater benefit from clinical sequencing. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results